Cerenome is trading 5.06% down at $1.69 after the October 1 regular session closed at $1.78; no clear company-specific catalyst for the after-hours decline was identified.
- The September 30 update reported 222 CNSide tests and $1.55 million in unaudited Q3 gross billings; it did not explain the October 1 move.
- The provided market context was mixed, so a broader-market cause is also unclear.